# Eyebright

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/eyebright

- Industry: Medical Devices & Equipment
- Headquarters: Beijing, China
- Website: www.ebmedical.com
- Total disclosed funding: $1.3M
- Latest round: Series C (Apr 18, 2018)
- Investors on record: 4

## About

Established in 2010 and based in Beijing, China, Eyebright is a provider of ophthalmic medical devices that provides intraocular lenses. The company has been rated as a National High-tech Enterprise and a National Specialized, Refined, Featured and Original SMEs, and has branches in Shanghai, Suzhou, Chengdu, etc. It has the Beijing Engineering Laboratory for Ophthalmic Biomaterials and Diagnosis and Treatment Technology, and has cooperated with the National Engineering Technology Research Center for Ophthalmic Diagnosis and Treatment Equipment. In May 2025, Bosera Asset Management, Caitong Fund Management Co., Ltd., Lord Abbett China Asset Management Co.,ltd., JP Morgan Asset Management, ICBC Credit Suisse Asset Management, Maxwealth Fund Management Co.,Ltd. and E Fund Asset Management, acquired 3.59 million shares in Eyebright at CNY 79.2 a piece for CNY 284.61 million in a PIPE acquisition.

The company's products include spherical intraocular lenses, microscopic eye scissors, orthokeratology lenses, contact lenses, etc. Its products can be used for ophthalmic surgery, myopia prevention and control, and vision care.


The company generates revenue by providing ophthalmic medical devices and other products.

## Funding rounds

- Series C, Apr 18, 2018 — IPV Capital Partners, Shanghai Jianyi Private Equity Fund Management, K2VC
- Series A, May 1, 2013, $1.3M — Lotus Lake Capital

## Investors

- Lotus Lake Capital (https://capitalatlas.ai/funds/lotus-lake-capital) — Series A
- IPV Capital Partners (https://capitalatlas.ai/funds/ipv-capital-partners) — Series C
- Shanghai Jianyi Private Equity Fund Management (https://capitalatlas.ai/funds/shanghai-jianyi-private-equity-fund-management) — Series C
- K2VC (https://capitalatlas.ai/funds/k2vc) — Series C